R. Gonzalez - Concepedia

Author

R. Gonzalez

Pontificia Universidad Católica de Chile ORCID

Also Known As

Gonzalez, Rodrigo, González, Rodrigo, R Gonzalez, R González, R. Gonzalez, Raul E. Flores-Gonzalez, Raúl E. Flores-González, Ricardo J. Gonzalez, Rodrigo Gonzalez, Rodrigo González

Publications

626

Citations

H-Index

Concepts

All Affiliations

Pontificia Universidad Católica de Chile University of Colorado Anschutz Medical Campus

About

R. Gonzalez is an author at Pontificia Universidad Católica de Chile specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	320
2	Immunology	3	3	86
3	Public Health	1	1	12
4	Cell Biology	1	1	20
5	Emergency Medicine	1	1	12

R. Gonzalez

Publications

508

Citations

H-Index

Page 1

	Year	Citations
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with <i>BRAF</i> V600E mutation-positive metastatic melanoma. A. Ribas, K. B. Kim, Lynn M. Schuchter, Journal of Clinical Oncology Mutant BrafSkin CancerBraf GeneMedicineMelanoma	2011	131
Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience Evanthia Galanis, E. M. Hersh, Alison Stopeck, Journal of Clinical Oncology	1999	99
A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM) Peter Hersey, Jeff Sosman, Steven O’Day, Journal of Clinical Oncology ImmunologyImmunotherapeuticsImmunotherapyHumanized Monoclonal AntibodyOncology	2005	55
Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study R. Gonzalez, S. Ebbinghaus, T. K. Henthorn, Melanoma Research	1999	45
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) James Larkin, Vanna Chiarion‐Sileni, R. Gonzalez, European Journal of Cancer OncologyKey Patient SubgroupsMelanomaImmune Checkpoint InhibitorDermatology	2015	36
Effect of a Low-Protein Diet on Urinary Albumin Excretion in Uremic Patients M. Aparicio, J.-L. Bouchet, H. Gin, The Nephron journals/Nephron journals	1988	32
Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7) R. Gonzalez, Antoni Ribas, Adil Daud, Annals of Oncology Phase Ib StudyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2012	21
Factors That Predict Duration of Delayed Graft Function in Cadaveric Kidney Transplantation José Ignacio Barranco Domínguez, Fernando Espinosa Lira, P. Troncoso, Transplantation Proceedings Transplantation SurgeryUrologyTransplantationKidney TransplantPredict Duration	2009	20
Phase Ib/Ii Study of Lee011 (Cdk4/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma Michael Taylor, Jeff Sosman, R. Gonzalez, Annals of Oncology OncologyMedicineMelanomaBraf InhibitorPhase Ib/ii Study	2014	20
Duration of Delayed Graft Function Is an Important Predictor of 1-Year Serum Creatinine José Ignacio Barranco Domínguez, Fernando Espinosa Lira, Rolando Rebolledo, Transplantation Proceedings 1-Year Serum CreatinineUrologyTransplantationImportant PredictorKidney Transplant	2009	15

Page 1